Jecure

Versant finishes Fund V with $20M NASH startup

Versant Ventures' latest startup Jecure debuted on Wednesday with a $20M Series A to further its preclinical work in liver fibrosis and NASH.

By Juliet Preston

Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options

FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.

By FASENRA, Sponsored Content

Changes in Nurse Staffing Answer Clinician Demands

The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.

By Tomasz Rezik

Tackling Rising Drug Costs and Growing Popularity of GLP-1’s

See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.

By Quantum Health and MedCity News